These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29925790)

  • 1. Human Granzyme B Based Targeted Cytolytic Fusion Proteins.
    Hlongwane P; Mungra N; Madheswaran S; Akinrinmade OA; Chetty S; Barth S
    Biomedicines; 2018 Jun; 6(2):. PubMed ID: 29925790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells.
    Mungra N; Jordaan S; Hlongwane P; Naran K; Chetty S; Barth S
    Oncotarget; 2019 Jan; 10(8):897-915. PubMed ID: 30783518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
    Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
    Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.
    Niesen J; Hehmann-Titt G; Woitok M; Fendel R; Barth S; Fischer R; Stein C
    Cancer Lett; 2016 May; 374(2):229-40. PubMed ID: 26912070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.
    Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T
    Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.
    Bochicchio A; Jordaan S; Losasso V; Chetty S; Perera RC; Ippoliti E; Barth S; Carloni P
    Biomedicines; 2017 Feb; 5(1):. PubMed ID: 28536352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors.
    Qian X; Shi Z; Qi H; Zhao M; Huang K; Han D; Zhou J; Liu C; Liu Y; Lu Y; Yuan X; Zhao J; Kang C
    Theranostics; 2019; 9(25):7616-7627. PubMed ID: 31695790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD56+ putative natural killer cell lymphomas: production of cytolytic effectors and related proteins mediating tumor cell apoptosis?
    Ng CS; Lo ST; Chan JK; Chan WC
    Hum Pathol; 1997 Nov; 28(11):1276-82. PubMed ID: 9385933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition.
    Dälken B; Giesübel U; Knauer SK; Wels WS
    Cell Death Differ; 2006 Apr; 13(4):576-85. PubMed ID: 16179940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors.
    Kam CM; Hudig D; Powers JC
    Biochim Biophys Acta; 2000 Mar; 1477(1-2):307-23. PubMed ID: 10708866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B.
    Cheung LH; Zhao Y; Alvarez-Cienfuegos A; Mohamedali KA; Cao YJ; Hittelman WN; Rosenblum MG
    J Exp Clin Cancer Res; 2019 Jul; 38(1):332. PubMed ID: 31362764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery and therapeutic potential of human granzyme B.
    Kurschus FC; Jenne DE
    Immunol Rev; 2010 May; 235(1):159-71. PubMed ID: 20536562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood.
    Bratke K; Kuepper M; Bade B; Virchow JC; Luttmann W
    Eur J Immunol; 2005 Sep; 35(9):2608-16. PubMed ID: 16106370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD3-activated killer T cells: interferon-gamma and interleukin-10 cross-regulate granzyme B expression and the induction of major histocompatibility complex-unrestricted cytotoxicity.
    Fitzpatrick L; Makrigiannis AP; Kaiser M; Hoskin DW
    J Interferon Cytokine Res; 1996 Jul; 16(7):537-46. PubMed ID: 8836920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis induced by granzyme B-glycosaminoglycan complexes: implications for granule-mediated apoptosis in vivo.
    Galvin JP; Spaeny-Dekking LH; Wang B; Seth P; Hack CE; Froelich CJ
    J Immunol; 1999 May; 162(9):5345-50. PubMed ID: 10228010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions.
    Rosenblum MG; Barth S
    Curr Pharm Des; 2009; 15(23):2676-92. PubMed ID: 19689338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The peptide loop consisting of amino acids 139-157 of human granzyme B (fragmentin 2) contains an immunodominant epitope recognized by the mouse.
    Apostolidis VA; Browne KA; Smyth MJ; Trapani JA
    Mol Immunol; 1995 Aug; 32(12):909-17. PubMed ID: 7565817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granzymes in cytolytic lymphocytes--to kill a killer?
    Regner M; Müllbacher A
    Immunol Cell Biol; 2004 Apr; 82(2):161-9. PubMed ID: 15061769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells.
    Jordaan S; Akinrinmade OA; Nachreiner T; Cremer C; Naran K; Chetty S; Barth S
    Biomedicines; 2018 Mar; 6(1):. PubMed ID: 29510557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.